ğŸ§¬ GENE OF THE WEEK: CYP2C19

Plavix saves lives after heart attacksâ€”unless you're a poor metabolizer. Then it's no better than placebo.

CYP2C19 is a liver enzyme that activates clopidogrel (Plavix) and metabolizes PPIs, some antidepressants, and antifungals. 30% of people have variants that significantly affect drug response.

The Metabolizer Types:

âš¡ Ultra-Rapid Metabolizer (5-30%)
Drugs cleared too fast. PPIs less effective. May need higher doses.

âœ“ Normal Metabolizer (35-50%)
Standard drug response. Plavix works as expected.

âš ï¸ Intermediate Metabolizer (18-45%)
Reduced Plavix activation. Consider alternatives or dose adjustment.

ğŸš¨ Poor Metabolizer (2-15%)
Plavix essentially inactiveâ€”cannot convert prodrug to active form. Use prasugrel or ticagrelor instead.

Major Drugs Affected:

ğŸ’Š Clopidogrel (Plavix) â€” Antiplatelet
ğŸ’Š Omeprazole/Esomeprazole â€” PPIs
ğŸ’Š Citalopram/Escitalopram â€” SSRIs
ğŸ’Š Voriconazole â€” Antifungal

The Clinical Impact:

After a stent, poor metabolizers on Plavix have 3x higher risk of stent thrombosisâ€”a potentially fatal event.

The FDA now recommends CYP2C19 testing before prescribing Plavix. Yet most cardiologists still don't test.

A $200 pharmacogenomic test could be the difference between life and death.

ğŸ‘¨â€âš•ï¸ Physicians: Why aren't you using Bioscope.AI to offer true AI-powered precision medicine?

ğŸ§‘ Patients: Why isn't your physician using Bioscope.AI to maximize your healthy longevity?

#GeneOfTheWeek #CYP2C19 #Pharmacogenomics #Plavix #PrecisionMedicine #Bioscope
